15th Annual Conference of the British HIV Association 1-3 April 2009, Liverpool, UK

DARUNAVIR/RITONAVIR ONCE DAILY: A SINGLE-CENTRE COHORT EXPERIENCE

HIV Med 2009 Apr 1-3 (Suppl 1);15:12 (abstract no. O24)

C Scott, A Teague, M Bower, B Gazzard and M Nelson
Chelsea & Westminster Hospital NHS Foundation Trust, London, UK

BACKGROUND: Darunavir (DRV) is a novel non-peptidic protease inhibitor (PI) with activity against wild type and protease inhibitor resistant HIV-1 when boosted with low dose ritonavir. We describe our experience of using once daily darunavir/ritonavir (900/100 mg) within the Chelsea & Westminster Hospital cohort.

METHODS: This prospective observational study followed a cohort of patients who received DRV/r (900/100 mg) od plus reverse transcriptase inhibitors (RTIs). CD4 count, viral load (VL) and routine safety bloods where measured at baseline, 0, 12, 24, 36 & 48 week intervals.

RESULTS: One hundred and eighty-seven patients commenced RTI + DRVr (900/100). All patients underwent phenotypic resistance testing confirming no baseline resistance to DRV. 24/187 patients were antiretroviral therapy naïve and 155/187 patients were anti-retroviral experienced. 108/155 patients switched with VL<50 copies/mL. Data were available for 187, 187, 154 and 102 patients at weeks 12, 24, 36 and 48 respectively. The proportion of patients achieving HIV VL <50 copies/mL (ITT) in the treatment naïve group was 54% at week 12, 79% at week 24, 83% at week 36 and 78% at week 48. In the treatment experienced group the proportion of patients with HIV RNA <50 copies/ mL (ITT) was 64% at week 12, 59% at week 24, 57% at week 36 and 58% at week 48. 108 individuals switched to DRVr with an undetectable HIV VL. The proportion maintaining HIV VL <50 copies/mL was 72% at week 48 (ITT). 4 virological failures were observed in this group due to poor adherence. No DRV resistance was identified. 32/187 patients discontinued therapy. Main reasons for discontinuation were diarrhoea and patient driven treatment interruption. 7/108 patients were lost to follow up.

CONCLUSIONS: In this cohort of treatment naïve and experienced patients with no background PI resistance, once daily darunavir/ritonavir (900/100 mg) is both effective in terms of virological suppression and well tolerated.

2009-04-01
O24

Copyright © 2009 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD